From: Virological failure among adolescents on ART, Harare City, 2017- a case-control study
Variable | Category | Cases (%) | Controls (%) | OR | 95%CI |
---|---|---|---|---|---|
Being on other medication | Yes | 10 (10) | 7 (7) | 1.48 | 0.54–4.04 |
No | 92 (90) | 95 (93) | |||
WHO staging | 3&4 | 60 (59) | 32 (33) | 3.13 | 1.76–5.55 |
1&2 | 42 (41) | 70 (67) | |||
CD4 count | ≤350 | 87 (85) | 56 (55) | 4.76 | 2.43–9.33 |
> 350 | 15 (15) | 46 (45) | |||
Duration on ART | ≤18 months | 84(82) | 86(84) | 0.87 | 0.41–1.82 |
> 18 months | 18(18) | 16(16) | |||
Chronic illness | Yes | 15 (15) | 6 (6) | 2.76 | 1.02–7.42 |
No | 87(15) | 96 (92) | |||
Drug S/E | Yes | 18 (18) | 12 (12) | 1.61 | 0.73–3.53 |
No | 84 (82) | 90 (88) | |||
Having no history of OIs | Yes | 63(62) | 70(69) | 0.67 | 0.38–1.21 |
No | 39(38) | 32(31) | |||
TDF + 3TC + EFV | Yes | 19(19) | 38(37) | 0.34 | 0.20–0.73 |
No | 83(81) | 64(63) | |||
Being on 2nd line treatment | Yes | 26 (25) | 5 (5) | 0.15 | 0.06–0.4 |
No | 76 (75) | 97 (95) |